Sage Therapeutics (SAGE)
(Real Time Quote from BATS)
$12.53 USD
+0.24 (1.95%)
Updated Jul 22, 2024 11:04 AM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SAGE 12.53 +0.24(1.95%)
Will SAGE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SAGE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SAGE
SAGE Rides on Zurzuvae Sales, Pipeline Setbacks a Concern
SAGE's Huntington's Disease Study Meets Primary Endpoint
SAGE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
Other News for SAGE
Netflix To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Friday
Mizuho Securities Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)
Sage Therapeutics price target lowered by $2 at Mizuho, here's why
Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
Noteworthy Tuesday Option Activity: SAGE, OPEN, CORZ